| Melissa Jean Costa, PHARMD | |
|
71 Lowell Rd, Hudson, NH 03051-4801 | |
| (617) 797-7042 | |
| Not Available |
| Full Name | Melissa Jean Costa |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 71 Lowell Rd, Hudson, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639381056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 26341 (Massachusetts) | Secondary |
| 183500000X | Pharmacist | 3445 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Jean Costa, PHARMD 35 Burlington Rd, Bedford, MA 01730-1307 Ph: (617) 797-7042 | Melissa Jean Costa, PHARMD 71 Lowell Rd, Hudson, NH 03051-4801 Ph: (617) 797-7042 |
News Archive
Determining how the law will be applied will be the next big battle in health reform and lobbyists are gearing up to influence implementation. "Congress gave sweeping power to federal agencies, especially (HHS), to fill in gaps lawmakers left in the 906-page legislation — an effort that will take years. The law refers more than 1,000 times to Cabinet secretaries who will make decisions on how to carry out the law. For example, the law requires insurance companies to spend 80% of premiums on medical claims, as opposed to administrative costs, by 2011. But it directs the health department to decide whether gray-area expenses, such as health-and-wellness programs offered by insurers, count as care or overhead."
A new review of studies from the University of Cincinnati (UC) shows that a little shove from the workplace may actually be the ticket to dropping weight.
The UC Davis Department of Pediatrics has received a $2 million, five-year grant from the Agency for Healthcare Research and Quality to fund a new telemedicine program for children in remote communities.
A variant in the glucocorticoid receptor gene may be associated with increased body fat and insulin resistance, show study findings.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
› Verified 8 days ago
Stephanie Lynne Lavallee, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 90 Derry St, Hudson, NH 03051 Phone: 603-880-0248 Fax: 603-889-0567 | |
Tatyana Borisyuk, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 71 Lowell Rd, Hudson, NH 03051 Phone: 603-882-6335 | |
Diane Smith Howes, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Walmart Blvd, Hudson, NH 03051 Phone: 603-598-6533 | |
Steven Surrette, PHARM.D., MBA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24a Chandler Ct, Hudson, NH 03051 Phone: 401-368-6247 | |
Mrs. Kyra Kristine Messina, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 77 Derry Rd, Hudson, NH 03051 Phone: 603-882-2301 Fax: 603-598-8366 | |
Renee Tavares, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 90 Derry St, Hudson, NH 03051 Phone: 603-880-0248 | |
Karen M Allard, BS RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 254 Lowell Rd, Hudson, NH 03051 Phone: 603-598-4638 |